Nomura Holdings
BHVN

Nomura Holdings’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Nomura Holdings’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-39,700
Closed -$4.64M – 2318
2022
Q1 		$4.64M Sell
39,700
-38,900
-49% -$4.85M 0.01% 642
2021
Q4 		$10.6M Buy
+78,600
New +$10M 0.03% 451
2019
Q3 		– Sell
-5,000
Closed -$216K – 1521
2019
Q2 		$216K Buy
+5,000
New +$282K ﹤0.01% 1029

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Nomura Holdings's BHVN Position: Q4 2022 in Review

Nomura Holdings sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 38,177 shares — an estimated $5.62M sold.

Nomura Holdings first reported a position in BHVN in Q2 2019 and held it in 8 quarters. The position peaked at $5.62M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Nomura Holdings reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Nomura Holdings sold 38,177 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $5.62M.
  • Nomura Holdings first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019 and held it in 8 quarters.
  • Nomura Holdings's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $5.62M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Nomura Holdings's 13F filing for Q4 2022, filed 14 Feb 2023.